 | • レポートコード：MRC2303B010 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の医薬品アイソレータ市場規模が予測期間中（2022～2027年）に年平均10％上昇すると推測されています。本調査書では、医薬品アイソレータの世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（クローズドアイソレーターシステム、オープンアイソレーターシステム）分析、用途別（無菌アイソレーター、閉込めアイソレーター、その他）分析、エンドユーザー別（製薬・バイオテクノロジー企業、研究所、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、Getimge AB、Chiyoda Corporation、Azbil Corporation、Germfree MBRAUN、Wabash National Corporation、NuAire、ITECO s.r.l、COMECER s.p.A、Hosokawa、Hecht Technologie GmbH、TEMA SINERGIE S.p.A、Bioquell Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の医薬品アイソレータ市場規模：種類別 - クローズドアイソレーターシステムの市場規模 - オープンアイソレーターシステムの市場規模 ・世界の医薬品アイソレータ市場規模：用途別 - 無菌アイソレーターにおける市場規模 - 閉込めアイソレーターにおける市場規模 - その他用途における市場規模 ・世界の医薬品アイソレータ市場規模：エンドユーザー別 - 製薬・バイオテクノロジー企業における市場規模 - 研究所における市場規模 - その他エンドユーザーにおける市場規模 ・世界の医薬品アイソレータ市場規模：地域別 - 北米の医薬品アイソレータ市場規模 アメリカの医薬品アイソレータ市場規模 カナダの医薬品アイソレータ市場規模 メキシコの医薬品アイソレータ市場規模 … - ヨーロッパの医薬品アイソレータ市場規模 ドイツの医薬品アイソレータ市場規模 イギリスの医薬品アイソレータ市場規模 フランスの医薬品アイソレータ市場規模 … - アジア太平洋の医薬品アイソレータ市場規模 中国の医薬品アイソレータ市場規模 日本の医薬品アイソレータ市場規模 インドの医薬品アイソレータ市場規模 … - 南米/中東の医薬品アイソレータ市場規模 南アフリカの医薬品アイソレータ市場規模 ブラジルの医薬品アイソレータ市場規模 アルゼンチンの医薬品アイソレータ市場規模 … ・競争状況 ・市場機会・将来動向 |
The Pharmaceutical Isolator Market is projected to register a CAGR of 10% during the forecast period (2022-2027).
The coronavirus outbreak increased the demand for pharmaceuticals, resulting in the growth of the pharmaceutical isolator market during the pandemic. For instance, as per an article published in July 2020, titled’ Short and Long Term Impact of COVID-19 on the Pharmaceutical Sector’ mentioned that COVID-19 increased the demand for prescription medicines, vaccines, and medical devices. Such studies prove the increase in demand for pharmaceutical isolators in the pharmaceutical industry. Moreover, the companies are performing clinical trials to curb the spread of the COVID-19 virus. For instance, Comecer developed the VaxISO Upstream isolator, the new dedicated stand-alone isolator for vaccine research and final formulation. Thus, increased clinical trials will lead to vital opportunities for the pharmaceutical isolator providers for biopharmaceutical companies.
Major factors such as greater sterility assurance of the pharmaceutical isolators are expected to drive the market’s growth during the forecast period. The immense sterility assurance of pharmaceutical isolators results in expanding the market demand. The preparations of the pharmaceutical manufacturing process include the inclusion of Active pharmaceutical ingredients with high potency, which require extreme caution and sterile environments assuring the contents from contamination. The pharmaceutical isolator satisfies the needs of the sterile environment n the manufactured process and delivers the desired finished product.
Moreover, increase in research and development expenditure in pharmaceutical research the market is expected to see a surge over the forecast period. For instance, according to the Pharmaceutical Research and Manufacturers of America data updates from September 2021, since 2000, PhRMA member companies have invested more than USD 1.1 Trillion in the search for new treatments and cures, including USD 102.3 Billion in 2021 alone. Furthermore, these are expected to increase further over the forecast period.
Moreover, as per an article published by Inos in May 2020, titled ‘Benefits of Aseptic Isolators’, positive pressure is maintained in the isolator to ensure that particles from the setup room will not enter the isolator and contamination does not take place. Aseptic isolators are routinely found within the pharmaceutical industry and are widely used for sterile injectable drug filling and sterile & pharmacy drug compounding. Thus, the advantage provided by the pharmaceutical isolators is expected to increase the adoption of pharmaceutical isolators over the forecast period.
The increasing innovative launches by the market players to meet the growing demand of the end users is expected to boost the growth of the market. For instance, in April 2021, ILC combined Solo’s rich history in single-use isolators with its expertise in flexible powder handling solutions. Moreover, in April 2021, ILC Dover launched a flexible aseptic isolator soloPURE for pharma and biopharma processing. ILC Dover brings one such solution to the table in the form of its fully disposable, single-use chamber and CAPEX-efficient soloPURE. The flexible aseptic isolator is a cost-effective, closed-barrier system for sterile manufacturing. Therefore, the above factors are expected to drive the market’s growth.
However, the availability of alternatives is expected to hinder market growth.
Pharmaceutical Isolator Market Trends
The Pharmaceutical and Biotechnology companies Segment is Expected to Witness Growth Over the Forecast Period
The sudden outbreak of COVID-19 had increased the demand for biologics to treat the infected people and provide vaccinations. The pharmaceutical and biotechnology segments are expected to hold the major share in the forecast period owing to the novel drug development and protein pharmaceutical synthesis using recombinant DNA technology.
Key factors such as increasing expenditure in the research and development by the pharmaceuticals and biotechnology industries to develop protein-based therapy are expected to significantly impact the market’s growth. According to the data published by Organisation for Economic Co-Operation and Development (OECD) in 2020, the pharmaceutical industry spent nearly USD 101 Billion on Research and Development in the OECD countries. Also, the same source reported that global R&D spending by the largest publicly- traded companies grew 13.7% annually. Therefore, the increasing expenditure on research and development by the pharmaceutical and biotechnology industries to develop their product pipeline is expected to boost the growth of the expression vectors market.
Moreover, in August 2022, Azzur Training Center announces the release of a comprehensive training course catalog spanning current good manufacturing practices (cGMP), regulatory requirements, industry manufacturing skills, and quality systems.
Hence, the pharmaceutical and biotechnology industries are expected to hold a significant share in the market during the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The increase in the adoption of highly advanced techniques and systems in genomics and proteomics, novel drug discovery, and development is expected to boost the market’s growth in the North American region. Also, the increasing funding from government organizations for research and development activities in the United States is a major contributing factor to the market growth in this region. According to the data published by the National Center for Biotechnology Information (NCBI), Biotechnology funding by the National Institute of Health (NIH) was around USD 7.77 Billion during the fiscal year 2020. Also, the data published by the Federation of American scientists reported that federal funding for research and development grew 5.9% in 2020 compared to 2019, which was USD 138.9 Billion. The Nation’s 42 federally funded research and development centers spend around USD 23.5 Billion on research and development in the fiscal year 2020. Additionally, the presence of major market players in this region is also a major factor in the growth of the market in this region.
Thus, the market is expected to witness significant growth during the forecast period due to the abovementioned factors.
Pharmaceutical Isolator Market Competitor Analysis
The Pharmaceutical isolators market is fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Getimge AB, Chiyoda Corporation, Azbil Corporation, Germfree MBRAUN, Wabash National Corporation, NuAire, ITECO s.r.l, COMECER s.p.s, Hosokawa, Hecht Technologie GmbH, TEMA SINERGIE S.p.A, Bioquell Inc and Others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Need of Sterility and Assurance of Pharmaceutical Isolator
4.2.2 Low Operational Cost of Pharmaceutical Isolators
4.3 Market Restraints
4.3.1 Availability of Alternatives
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Closed Isolator Systems
5.1.2 Open Isolator Systems
5.2 By Application
5.2.1 Aseptic Isolators
5.2.2 Containment Isolators
5.2.3 Others
5.3 By End user
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Research Laboratories
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Getimge AB
6.1.2 Chiyoda Corporation
6.1.3 Azbil Corporation
6.1.4 Germfree MBRAUN
6.1.5 Wabash National Corporation
6.1.6 NuAire
6.1.7 ITECO s.r.l
6.1.8 COMECER s.p.A
6.1.9 Hosokawa
6.1.10 Hecht Technologie GmbH
6.1.11 TEMA SINERGIE S.p.A
6.1.12 Bioquell Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS